Cargando…

Insulin resistance limits corneal nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control

AIMS/INTRODUCTION: This study aimed to investigate whether insulin resistance (IR) in individuals with type 2 diabetes undergoing intensive glycemic control determines the extent of improvement in neuropathy. MATERIALS AND METHODS: This was an exploratory substudy of an open‐label, randomized contro...

Descripción completa

Detalles Bibliográficos
Autores principales: Ponirakis, Georgios, Abdul‐Ghani, Muhammad A, Jayyousi, Amin, Zirie, Mahmoud A, Al‐Mohannadi, Salma, Almuhannadi, Hamad, Petropoulos, Ioannis N, Khan, Adnan, Gad, Hoda, Migahid, Osama, Megahed, Ayman, Qazi, Murtaza, AlMarri, Fatema, Al‐Khayat, Fatima, Mahfoud, Ziyad, DeFronzo, Ralph, Malik, Rayaz A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565403/
https://www.ncbi.nlm.nih.gov/pubmed/34002953
http://dx.doi.org/10.1111/jdi.13582
_version_ 1784593819480621056
author Ponirakis, Georgios
Abdul‐Ghani, Muhammad A
Jayyousi, Amin
Zirie, Mahmoud A
Al‐Mohannadi, Salma
Almuhannadi, Hamad
Petropoulos, Ioannis N
Khan, Adnan
Gad, Hoda
Migahid, Osama
Megahed, Ayman
Qazi, Murtaza
AlMarri, Fatema
Al‐Khayat, Fatima
Mahfoud, Ziyad
DeFronzo, Ralph
Malik, Rayaz A
author_facet Ponirakis, Georgios
Abdul‐Ghani, Muhammad A
Jayyousi, Amin
Zirie, Mahmoud A
Al‐Mohannadi, Salma
Almuhannadi, Hamad
Petropoulos, Ioannis N
Khan, Adnan
Gad, Hoda
Migahid, Osama
Megahed, Ayman
Qazi, Murtaza
AlMarri, Fatema
Al‐Khayat, Fatima
Mahfoud, Ziyad
DeFronzo, Ralph
Malik, Rayaz A
author_sort Ponirakis, Georgios
collection PubMed
description AIMS/INTRODUCTION: This study aimed to investigate whether insulin resistance (IR) in individuals with type 2 diabetes undergoing intensive glycemic control determines the extent of improvement in neuropathy. MATERIALS AND METHODS: This was an exploratory substudy of an open‐label, randomized controlled trial of individuals with poorly controlled type 2 diabetes treated with exenatide and pioglitazone or insulin to achieve a glycated hemoglobin <7.0% (<53 mmol/mol). Baseline IR was defined using homeostasis model assessment of IR, and change in neuropathy was assessed using corneal confocal microscopy. RESULTS: A total of 38 individuals with type 2 diabetes aged 50.2 ± 8.5 years with (n = 25, 66%) and without (n = 13, 34%) IR were studied. There was a significant decrease in glycated hemoglobin (P < 0.0001), diastolic blood pressure (P < 0.0001), total cholesterol (P < 0.01) and low‐density lipoprotein (P = 0.05), and an increase in bodyweight (P < 0.0001) with treatment. Individuals with homeostasis model assessment of IR <1.9 showed a significant increase in corneal nerve fiber density (P ≤ 0.01), length (P ≤ 0.01) and branch density (P ≤ 0.01), whereas individuals with homeostasis model assessment of IR ≥1.9 showed no change. IR was negatively associated with change in corneal nerve fiber density after adjusting for change in bodyweight (P < 0.05). CONCLUSIONS: Nerve regeneration might be limited in individuals with type 2 diabetes and IR undergoing treatment with pioglitazone plus exenatide or insulin to improve glycemic control.
format Online
Article
Text
id pubmed-8565403
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-85654032021-11-09 Insulin resistance limits corneal nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control Ponirakis, Georgios Abdul‐Ghani, Muhammad A Jayyousi, Amin Zirie, Mahmoud A Al‐Mohannadi, Salma Almuhannadi, Hamad Petropoulos, Ioannis N Khan, Adnan Gad, Hoda Migahid, Osama Megahed, Ayman Qazi, Murtaza AlMarri, Fatema Al‐Khayat, Fatima Mahfoud, Ziyad DeFronzo, Ralph Malik, Rayaz A J Diabetes Investig Articles AIMS/INTRODUCTION: This study aimed to investigate whether insulin resistance (IR) in individuals with type 2 diabetes undergoing intensive glycemic control determines the extent of improvement in neuropathy. MATERIALS AND METHODS: This was an exploratory substudy of an open‐label, randomized controlled trial of individuals with poorly controlled type 2 diabetes treated with exenatide and pioglitazone or insulin to achieve a glycated hemoglobin <7.0% (<53 mmol/mol). Baseline IR was defined using homeostasis model assessment of IR, and change in neuropathy was assessed using corneal confocal microscopy. RESULTS: A total of 38 individuals with type 2 diabetes aged 50.2 ± 8.5 years with (n = 25, 66%) and without (n = 13, 34%) IR were studied. There was a significant decrease in glycated hemoglobin (P < 0.0001), diastolic blood pressure (P < 0.0001), total cholesterol (P < 0.01) and low‐density lipoprotein (P = 0.05), and an increase in bodyweight (P < 0.0001) with treatment. Individuals with homeostasis model assessment of IR <1.9 showed a significant increase in corneal nerve fiber density (P ≤ 0.01), length (P ≤ 0.01) and branch density (P ≤ 0.01), whereas individuals with homeostasis model assessment of IR ≥1.9 showed no change. IR was negatively associated with change in corneal nerve fiber density after adjusting for change in bodyweight (P < 0.05). CONCLUSIONS: Nerve regeneration might be limited in individuals with type 2 diabetes and IR undergoing treatment with pioglitazone plus exenatide or insulin to improve glycemic control. John Wiley and Sons Inc. 2021-06-19 2021-11 /pmc/articles/PMC8565403/ /pubmed/34002953 http://dx.doi.org/10.1111/jdi.13582 Text en © 2021 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Articles
Ponirakis, Georgios
Abdul‐Ghani, Muhammad A
Jayyousi, Amin
Zirie, Mahmoud A
Al‐Mohannadi, Salma
Almuhannadi, Hamad
Petropoulos, Ioannis N
Khan, Adnan
Gad, Hoda
Migahid, Osama
Megahed, Ayman
Qazi, Murtaza
AlMarri, Fatema
Al‐Khayat, Fatima
Mahfoud, Ziyad
DeFronzo, Ralph
Malik, Rayaz A
Insulin resistance limits corneal nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control
title Insulin resistance limits corneal nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control
title_full Insulin resistance limits corneal nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control
title_fullStr Insulin resistance limits corneal nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control
title_full_unstemmed Insulin resistance limits corneal nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control
title_short Insulin resistance limits corneal nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control
title_sort insulin resistance limits corneal nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565403/
https://www.ncbi.nlm.nih.gov/pubmed/34002953
http://dx.doi.org/10.1111/jdi.13582
work_keys_str_mv AT ponirakisgeorgios insulinresistancelimitscornealnerveregenerationinpatientswithtype2diabetesundergoingintensiveglycemiccontrol
AT abdulghanimuhammada insulinresistancelimitscornealnerveregenerationinpatientswithtype2diabetesundergoingintensiveglycemiccontrol
AT jayyousiamin insulinresistancelimitscornealnerveregenerationinpatientswithtype2diabetesundergoingintensiveglycemiccontrol
AT ziriemahmouda insulinresistancelimitscornealnerveregenerationinpatientswithtype2diabetesundergoingintensiveglycemiccontrol
AT almohannadisalma insulinresistancelimitscornealnerveregenerationinpatientswithtype2diabetesundergoingintensiveglycemiccontrol
AT almuhannadihamad insulinresistancelimitscornealnerveregenerationinpatientswithtype2diabetesundergoingintensiveglycemiccontrol
AT petropoulosioannisn insulinresistancelimitscornealnerveregenerationinpatientswithtype2diabetesundergoingintensiveglycemiccontrol
AT khanadnan insulinresistancelimitscornealnerveregenerationinpatientswithtype2diabetesundergoingintensiveglycemiccontrol
AT gadhoda insulinresistancelimitscornealnerveregenerationinpatientswithtype2diabetesundergoingintensiveglycemiccontrol
AT migahidosama insulinresistancelimitscornealnerveregenerationinpatientswithtype2diabetesundergoingintensiveglycemiccontrol
AT megahedayman insulinresistancelimitscornealnerveregenerationinpatientswithtype2diabetesundergoingintensiveglycemiccontrol
AT qazimurtaza insulinresistancelimitscornealnerveregenerationinpatientswithtype2diabetesundergoingintensiveglycemiccontrol
AT almarrifatema insulinresistancelimitscornealnerveregenerationinpatientswithtype2diabetesundergoingintensiveglycemiccontrol
AT alkhayatfatima insulinresistancelimitscornealnerveregenerationinpatientswithtype2diabetesundergoingintensiveglycemiccontrol
AT mahfoudziyad insulinresistancelimitscornealnerveregenerationinpatientswithtype2diabetesundergoingintensiveglycemiccontrol
AT defronzoralph insulinresistancelimitscornealnerveregenerationinpatientswithtype2diabetesundergoingintensiveglycemiccontrol
AT malikrayaza insulinresistancelimitscornealnerveregenerationinpatientswithtype2diabetesundergoingintensiveglycemiccontrol